NIHR Manchester Biomedical Research Centre

What NIHR Manchester Biomedical Research Centre does

NIHR Manchester Biomedical Research Centre is a publicly funded translational research infrastructure hosted jointly by Manchester University NHS Foundation Trust and The University of Manchester, operating under the National Institute for Health and Care Research (NIHR). It was established in 2017 and is the largest NIHR Biomedical Research Centre outside the South East of England, having been awarded £64.1 million for the 2022-28 cycle — the largest single research award from NIHR to the city region. Its mission is to translate scientific discoveries into diagnostic tests and treatments for patients across Greater Manchester, Lancashire and South Cumbria.

The centre's core technology is organised into 13 research themes grouped across four clusters: Cancer (Prevention and Early Detection, Advanced Radiotherapy, Precision Medicine, Living with and Beyond Cancer), Inflammation (Rheumatic and Musculoskeletal Diseases, Respiratory Medicine, Dermatology, Integrative Cardiovascular Medicine), Under-Researched Conditions (Hearing Health, Mental Health, Rare Conditions), and Advanced Diagnostics and Therapeutics (Next Generation Phenotyping and Diagnostics, Next Generation Therapeutics). Underlying infrastructure includes a Trusted Research Environment for secure health-data analysis and a Patient and Public Involvement and Engagement (PPIEP) programme co-developed with NIHR Manchester Clinical Research Facility and Vocal. Concrete outputs include the 18SNP breast cancer risk test, a pyrosequencing diagnostic for aspergillosis treatment selection, and AI research covering predictive analytics and computer vision applied to retinal imaging for cardiovascular and neurological disease detection.

The business model is grant-funded rather than commercially priced. Primary revenue is the NIHR core award, supplemented by charitable grants (Wellcome Trust, Prevent Breast Cancer) and collaborative industry funding through an Innovation and Partnerships team that engages pharma, SMEs, MedTech, BioTech and in vitro diagnostic partners via pump-priming calls, co-design workshops and strategic partnership agreements. The organisation does not operate a commercial pricing model and does not distribute commercial products; instead it provides access to specialist facilities, clinical expertise, diverse patient populations and translational research infrastructure for collaborative research partners. Customers include NHS patients (the ultimate beneficiary), academic and clinical researchers, industry partners, and charity/public sector collaborators such as Health Innovation Manchester and the Northern Health Science Alliance.

Name

NIHR Manchester Biomedical Research Centre

Legal name

NIHR Manchester Biomedical Research Centre

Website

https://manchesterbrc.nihr.ac.uk

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

251–500 employees

Ownership category

akta.pro rank

Product category

Biomedical Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI)

akta.pro secondary industries

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD), Clinical Research & Trial Central Laboratories (HLAFAMAL), Public Research Universities with Academic Medical Centers (AMCs) (EDAHAAAC)

Keywords

• Translational biomedical research
• Clinical research collaboration
• Precision medicine development
• Experimental medicine programs
• Patient public involvement

Headquarters

HQ city

Manchester

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain

Revenue model

1. NIHR Core Funding: Awarded £64.1 million (2022-28) by the National Institute for Health and Care Research (NIHR) - the largest single research award given by NIHR to the city region.
2. Industry Collaboration Revenue: Revenue generated through collaborative commercial research with pharma, MedTech, BioTech and in vitro diagnostic companies, including pump-priming calls and strategic industry partnerships.
3. Charitable Foundation Grants: Additional funding from organizations such as Prevent Breast Cancer, Wellcome Trust, and other charitable bodies supporting specific research projects.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

Core offering

NIHR Manchester Biomedical Research Centre is a publicly funded translational research centre that conducts experimental medicine and clinical research across 13 research themes organised into 4 clusters (cancer, inflammation, under-researched conditions, and advanced diagnostics and therapeutics). The centre partners with NHS Trusts, the University of Manchester, industry and charities to translate scientific discoveries into diagnostic tests and treatments for patients across Greater Manchester, Lancashire and South Cumbria.

Product overview

NIHR Manchester Biomedical Research Centre is a translational research infrastructure (not a traditional product company) organized around 14 distinct research themes grouped into 4 clusters: Cancer (Advanced Radiotherapy, Precision Medicine, Prevention and Early Detection, Living with and Beyond Cancer), Inflammation (Dermatology, Integrative Cardiovascular Medicine, Respiratory Medicine, Rheumatic and Musculoskeletal Diseases), Under-Researched Conditions (Hearing Health, Mental Health, Rare Conditions, Children's Research), and Advanced Diagnostics and Therapeutics Catalyst (Next Generation Phenotyping and Diagnostics, Next Generation Therapeutics). The organization provides research collaboration services, innovation pathways for industry partners, education and training programs, and patient/public involvement infrastructure. The centre's primary offerings are research capabilities and partnerships rather than commercial products.

Differentiator

Problem solved

Functional benefit

Products and services

• Cancer Advanced Radiotherapy Research Theme
• Cancer Precision Medicine Research Theme
• Cancer Prevention and Early Detection Research Theme
• Living with and Beyond Cancer Research Theme
• Next Generation Phenotyping and Diagnostics Research Theme
• Next Generation Therapeutics Research Theme
• Hearing Health Research Theme
• Mental Health Research Theme
• Rare Conditions Research Theme
• Dermatology Research Theme
• Integrative Cardiovascular Medicine Research Theme
• Respiratory Medicine Research Theme
• Rheumatic and Musculoskeletal Diseases Research Theme
• Children's Research Theme
• Innovation and Partnerships Service
• Education and Training Programs
• Patient and Public Involvement and Engagement (PPIEP)
• 18SNP Breast Cancer Risk Test
• Pyrosequencing Diagnostic Test for Aspergillosis

Quantifiable outcome

• Largest BRC outside South East England with £64.1M funding
• +1 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability4 records

Feature3 records

Partnerships

16 partnerships are on record, tiered minor, strategic, primary and core.

• University of NottinghamminorStrategic or Co-development Partner · 1 January 2026Research partner in ArcTanGent Safe Listening festival research initiative.
• University of DerbyminorStrategic or Co-development Partner · 1 January 2026Research partner in ArcTanGent Safe Listening festival research initiative.
• PharmanoviastrategicTechnology or Integration · 1 January 2023Industry partner in RAD-PIT study developing Macimorelin diagnostic test protocol for teenagers and young adults receiving radiotherapy. Partnership involved co-design workshops with clinical team, Vocal, and patients/public.
• Manchester University NHS Foundation TrustprimaryStrategic or Co-development PartnerHost organisation for NIHR Manchester BRC, providing NHS infrastructure and clinical research capabilities.
• The University of ManchesterprimaryStrategic or Co-development PartnerHost organisation providing academic research expertise and world-leading researchers across 13 research themes.
• The Christie NHS Foundation TrustcoreStrategic or Co-development PartnerNHS Trust partner specializing in cancer care and research, hosting Living With and Beyond Cancer theme research.
• Northern Care Alliance NHS Foundation TrustcoreStrategic or Co-development PartnerNHS Trust partner contributing to research across multiple disease areas and clinical specialties.
• Lancashire Teaching Hospitals NHS Foundation TrustcoreStrategic or Co-development PartnerNHS Trust partner extending research reach across Lancashire region.
• Blackpool Teaching Hospitals NHS Foundation TrustcoreStrategic or Co-development PartnerNHS Trust partner serving the Blackpool and Fylde coast area.
• Greater Manchester Mental Health NHS Foundation TrustcoreStrategic or Co-development PartnerNHS Trust partner supporting mental health research theme.
• Manchester Academic Health Science CentrecoreStrategic or Co-development PartnerAcademic Health Science Centre driving research in health innovation across Greater Manchester.
• Health Innovation ManchestercoreStrategic or Co-development PartnerSupporting organisation facilitating quicker translation of research from discovery to improved patient care through connected health ecosystem.
• Northern Health Science AlliancecoreStrategic or Co-development PartnerAlliance connecting Northern universities and NHS Trusts to accelerate health research innovation.
• VocalcoreStrategic or Co-development PartnerPatient and public involvement organisation co-developing PPIEP strategy with NIHR Manchester BRC and CRF, ensuring inclusive research infrastructure.
• NIHR Manchester Clinical Research Facility (CRF)coreStrategic or Co-development PartnerJoint PPIEP strategy development and shared research infrastructure with NIHR Manchester CRF.
• ArcTanGent FestivalminorStrategic or Co-development PartnerUK's first Safe Listening festival partner hosting hearing health research activities implementing WHO global standards.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• NIHR UCL Hospitals Biomedical Research Centre: UCLH BRC is a London-based NIHR translational research centre hosted by University College London Hospitals NHS Foundation Trust and UCL. It shares the NIHR funding model and translational research mandate with Manchester BRC and is among the larger UK BRCs.
• NIHR Cambridge Biomedical Research Centre: Cambridge BRC is another NIHR-funded translational research centre hosted by Cambridge University Hospitals and the University of Cambridge. It shares the same funding mechanism, cluster structure, and industry collaboration model as Manchester BRC and is one of the larger UK BRCs.
• NIHR Newcastle Biomedical Research Centre: Newcastle BRC is a NIHR-funded translational research centre hosted by The Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University. It operates under the same translational model as Manchester BRC and is a fellow Northern NIHR BRC.
• NIHR Bristol Biomedical Research Centre: Bristol BRC is a NIHR-funded translational research centre hosted by University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol. It shares the same funding model, translational scope, and NHS-university partnership structure as Manchester BRC.
• NIHR Oxford Biomedical Research Centre: Oxford BRC is a sister NIHR-funded translational research centre hosted by Oxford University Hospitals NHS Foundation Trust and the University of Oxford. It operates the same funding model, governance structure, and translational mandate as Manchester BRC, making it the most directly comparable peer.
• NIHR King's College London Biomedical Research Centre: King's College London BRC is a NIHR-funded translational research centre operating under the same model as Manchester BRC, hosted by Guy's and St Thomas' and King's College Hospital NHS trusts. It is a direct peer in funding structure and translational scope.
• NIHR Imperial Biomedical Research Centre: Imperial BRC is a London-based NIHR-funded translational research centre hosted by Imperial College Healthcare NHS Trust and Imperial College London. It mirrors Manchester's translational model with a strong industry collaboration focus, and competes for similar pharma and MedTech partnerships.
• NIHR Leeds Biomedical Research Centre: Leeds BRC is a NIHR-funded translational research centre in the North of England hosted by Leeds Teaching Hospitals NHS Trust and the University of Leeds. It is a regional peer under the same funding and translational model, with some thematic overlap (e.g., musculoskeletal, cardiovascular).
• NIHR Birmingham Biomedical Research Centre: Birmingham BRC is a NIHR-funded translational research centre hosted by University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham. It operates under the same translational model as Manchester BRC and is one of the larger regional BRCs.
• NIHR Guy's and St Thomas' Biomedical Research Centre: Guy's and St Thomas' BRC is a NIHR-funded translational research centre in London that operates under the same funding mechanism and translational model as Manchester BRC, with overlapping clinical and biomedical research themes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks1 record

Key highlights7 records

Customer concentration

• Xx.com/ManchesterBRC
• YouTubeyoutube.com/channel/UCxOcXLZ-L1mw9wDFJz0gSXg
• LinkedInlinkedin.com/company/nihr-manchester-brc

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NIHR Manchester Biomedical Research Centre